A whopping $53.1M Series B will help Syros Pharmaceuticals advance toward clinic for cancer

Gene regulation startup Syros Pharmaceuticals has raised a $53.1 million from 16 investors, according to regulatory filings. This financing round was led by “a large, Boston-based public investment firm,” also includes new investors Polaris Partners, Aisling Capital and Redmile Group. The current investors – Flagship Ventures, ARCH Venture Partners, WuXi PharmaTech Corporate Ventuer Fund and […]